December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
1 citations
,
January 1976 in “Clinical Science” Minoxidil with a diuretic effectively lowers blood pressure in moderately hypertensive men with minimal side effects.
January 2016 in “Yanwaishang zhiye yanbing zazhi” Atropine and neosynephrine effectively prevent floppy iris syndrome during cataract surgery.
26 citations
,
June 1983 in “Journal of Hypertension” Minoxidil lowers blood pressure more effectively but has more side effects, so try hydralazine first.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
18 citations
,
January 1976 in “Drugs” New treatments improved blood pressure control in patients with resistant hypertension.
295 citations
,
September 2006 in “Cell Cycle” The conclusion is that using drugs to block the TOR pathway might slow aging and prevent age-related diseases.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
79 citations
,
October 2003 in “PubMed” Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
11 citations
,
June 2019 in “Journal of dermatology” New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
100 citations
,
March 1973 in “American Journal of Cardiology” Minoxidil effectively lowers blood pressure without major side effects.
17 citations
,
April 1975 in “The Journal of Pediatrics” Minoxidil effectively controls severe high blood pressure in children with few side effects.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
6 citations
,
June 2009 in “Clinical and Experimental Dermatology” Topical tacrolimus reduces certain growth factors in hair follicles.
June 2016 in “American Journal of Cardiology” The treatment successfully reopened blood flow in most patients and extended the use of their dialysis access with low risk.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
January 2004 in “Chinese Journal of Blood Purification” Minoxidil effectively manages severe hypertension in hemodialysis patients with minimal side effects.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
June 2011 in “British Journal of Urology” Regulatory challenges make developing combination therapies in urology difficult and costly.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” December 2025 in “Zenodo (CERN European Organization for Nuclear Research)”